P
Philip J. Clements
Researcher at University of California, Los Angeles
Publications - 186
Citations - 19693
Philip J. Clements is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: FEV1/FVC ratio & Interstitial lung disease. The author has an hindex of 65, co-authored 184 publications receiving 17198 citations. Previous affiliations of Philip J. Clements include Food and Drug Administration & University of Western Ontario.
Papers
More filters
Journal ArticleDOI
2013 classification criteria for systemic sclerosis: An american college of rheumatology/European league against rheumatism collaborative initiative
Frank H J van den Hoogen,Dinesh Khanna,Jaap Fransen,Sindhu R Johnson,Murray Baron,Alan Tyndall,Marco Matucci-Cerinic,Raymond P. Naden,Thomas A. Medsger,Patricia Carreira,Gabriela Riemekasten,Philip J. Clements,Christopher P. Denton,Oliver Distler,Yannick Allanore,Daniel E. Furst,Armando Gabrielli,Maureen D. Mayes,Jacob M van Laar,James R. Seibold,László Czirják,Virginia D. Steen,Murat Inanc,Otylia Kowal-Bielecka,Ulf Müller-Ladner,Gabriele Valentini,Douglas J. Veale,Madelon C. Vonk,Ulrich A Walker,Lorinda Chung,David H. Collier,David H. Collier,Mary Ellen Csuka,Barri J. Fessler,Serena Guiducci,Ariane L. Herrick,Vivien Hsu,Sergio A. Jimenez,Bashar Kahaleh,Bashar Kahaleh,Peter A. Merkel,Stanislav Sierakowski,Richard M. Silver,Robert W. Simms,Robert W. Simms,John Varga,Janet E. Pope +46 more
TL;DR: The ACR/EULAR classification criteria for SSc performed better than the 1980 ACR criteria and should allow for more patients to be classified correctly as having the disease.
Journal ArticleDOI
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative
Frank H J van den Hoogen,Dinesh Khanna,Jaap Fransen,Sindhu R Johnson,Murray Baron,Alan Tyndall,Marco Matucci-Cerinic,Raymond P. Naden,Thomas A. Medsger,Patricia Carreira,Gabriela Riemekasten,Philip J. Clements,Christopher P. Denton,Oliver Distler,Yannick Allanore,Daniel E. Furst,Armando Gabrielli,Maureen D. Mayes,Jacob M van Laar,James R. Seibold,László Czirják,Virginia D. Steen,Murat Inanc,Otylia Kowal-Bielecka,Ulf Müller-Ladner,Gabriele Valentini,Douglas J. Veale,Madelon C. Vonk,Ulrich A Walker,Lorinda Chung,David H. Collier,David H. Collier,Mary Ellen Csuka,Barri J. Fessler,Serena Guiducci,Ariane L. Herrick,Ariane L. Herrick,Vivien Hsu,Sergio A. Jimenez,Bashar Kahaleh,Peter A. Merkel,Peter A. Merkel,Stanislav Sierakowski,Richard M. Silver,Robert W. Simms,John Varga,Janet E. Pope +46 more
TL;DR: The ACR/EULAR classification criteria for SSc performed better than the 1980 ACR criteria and should allow for more patients to be classified correctly as having the disease.
Journal ArticleDOI
Cyclophosphamide versus placebo in scleroderma lung disease.
Donald P. Tashkin,Robert Elashoff,Philip J. Clements,Jonathan G. Goldin,Michael D. Roth,Daniel E. Furst,Edgar Arriola,Richard M. Silver,Charlie Strange,Marcy B. Bolster,James R. Seibold,David J. Riley,Vivien Hsu,John Varga,Dean E. Schraufnagel,Arthur C. Theodore,Robert W. Simms,Robert A. Wise,Fredrick M. Wigley,Barbara White,Virginia D. Steen,Charles A. Read,Maureen D. Mayes,Ed Parsley,Kamal K. Mubarak,M. Kari Connolly,Jeffrey A. Golden,Mitchell A. Olman,B. J. Fessler,Naomi F. Rothfield,Mark L. Metersky +30 more
TL;DR: One year of oral cyclophosphamide in patients with symptomatic scleroderma-related interstitial lung disease had a significant but modest beneficial effect on lung function, dyspnea, thickening of the skin, and the health-related quality of life.
Journal ArticleDOI
Update of EULAR recommendations for the treatment of systemic sclerosis
Otylia Kowal-Bielecka,Jaap Fransen,Jérôme Avouac,Mike O Becker,Mike O Becker,Agnieszka Kulak,Yannick Allanore,Oliver Distler,Philip J. Clements,Maurizio Cutolo,László Czirják,Nemanja Damjanov,Francesco Del Galdo,Christopher P. Denton,Jörg H W Distler,Ivan Foeldvari,Kim Figelstone,Marc Frerix,Daniel E. Furst,Serena Guiducci,Nicolas Hunzelmann,Dinesh Khanna,Marco Matucci-Cerinic,Ariane L. Herrick,Frank J. A. van den Hoogen,Jacob M van Laar,Gabriela Riemekasten,Richard M. Silver,Vanessa Smith,Vanessa Smith,Alberto Sulli,Ingo H. Tarner,Alan Tyndall,Joep Welling,Frederic Wigley,Gabriele Valentini,Ulrich A Walker,Francesco Zulian,Ulf Müller-Ladner +38 more
TL;DR: In this article, the European League against Rheumatism (EULAR) developed a set of recommendations for the treatment of systemic sclerosis (SSc) with attention to new therapeutic questions.
Journal ArticleDOI
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial
Donald P. Tashkin,Michael D. Roth,Philip J. Clements,Daniel E. Furst,Dinesh Khanna,Eric C. Kleerup,Jonathan G. Goldin,Edgar Arriola,Elizabeth R. Volkmann,Suzanne Kafaja,Richard M. Silver,Virginia D. Steen,Charlie Strange,Robert A. Wise,Fredrick M. Wigley,Maureen D. Mayes,David J. Riley,Sabiha Hussain,Shervin Assassi,Vivien Hsu,Bela Patel,Kristine Phillips,Fernando J. Martinez,Jeffrey A. Golden,M. Kari Connolly,John Varga,Jane Dematte,Monique Hinchcliff,Aryeh Fischer,Jeffrey J. Swigris,Richard T. Meehan,Arthur C. Theodore,Robert W. Simms,Suncica Volkov,Dean E. Schraufnagel,Mary Beth Scholand,Tracy M. Frech,Jerry A. Molitor,Kristin B. Highland,Charles A. Read,Marvin J. Fritzler,Grace Kim,Chi-Hong Tseng,Robert Elashoff +43 more
TL;DR: In this article, the authors used a modified intention-to-treat analysis using an inferential joint model combining a mixed-effects model for longitudinal outcomes and a survival model to handle non-ignorable missing data.